In Europe, 40% of all platelet concentrates undergo either bacterial screening or pathogen inactivation. This percentage may increase even more in 2018 as major European countries are currently taking action to mitigate the risk of septic transfusion reactions and emerging pathogens.
Perhaps you’d like to follow their example, but you’re not sure how to integrate pathogen inactivation into your existing platelet production processes, or you believe that it’s financially out of reach.
We have good news for you. The INTERCEPT™ Triple Storage Processing Set offers a fast track to improved blood safety.
Would you like to learn more about current blood safety challenges, the benefits of INTERCEPT and the Triple Storage Processing Set?
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.